JZJ(605266)2025-01-17 11:35Financial Performance - The company expects a net profit for 2024 to decrease by 68.78% to 65.50%, estimating a range of 27,143.04 million to 28,504.76 million compared to 41,441.15 million in the previous year[3]. - The net profit excluding non-recurring gains and losses is projected to decline by 69.15% to 65.91%, with an estimated range of 26,312.12 million to 27,617.90 million compared to 39,937.30 million last year[4]. - The decline in profit is attributed to intensified market competition and the impact of ongoing pharmaceutical reform policies, leading to stagnant revenue growth and increased pressure on profits[8]. Business Strategy - The company plans to slow down store expansion and focus on improving the performance of existing stores, enhancing operational efficiency, and controlling costs[17]. - The company aims to transform the challenges posed by policy and reform pressures into opportunities by deepening its transition towards health products and professional services[17]. Regulatory Compliance - The company is actively cooperating with regulatory authorities to ensure compliance with medical insurance regulations and to implement outpatient coordination policies[18]. Shareholder Value - The company has initiated a share repurchase mechanism to maintain market value and enhance investor confidence, with ongoing repurchase operations during the reporting period[19]. - The preliminary financial data provided is subject to final confirmation in the official 2024 annual report, and investors are advised to be aware of investment risks[21]. Revenue Composition - The proportion of medical insurance revenue in the main business decreased from 52% in 2022 to 44% in the first nine months of 2024[9].